Any Patient Treated With MB-105NCT07340814
A Long-term Follow-up Study of Patients Who Received MB-105
An observational study of Any Patient Treated With MB-105, run by March Biosciences Inc.
Trial summary
This study is to fulfil the regulatory requirement for 15-year follow-up for patients treated with MB-105 in any study Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Any Patient Treated With MB-105
- What is being tested?
- MB-105
- How many people
- 40 participants
- Where
- No sites listed yet
- Study dates
- 27 Feb 2026to 15 Oct 2040
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Patients who previously received MB-105 and consent to participate
Who may be able to join
- Received MB-105 Signed informed consent Agree to transfer of samples from previous study Able to comply with study requirements
Who cannot join
- N/A
About this study
This study is to fulfil the regulatory requirement for 15-year follow-up for patients treated with MB-105 in any study
Read the detailed description
This study is for long term follow up of efficacy and safety for any patient treated with MB-105 who has consented to joining the LTFU study. There are no exclusion criteria.
- Conditions
- Any Patient Treated With MB-105
- Being tested
- MB-105
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MB-105Biological
This is an observational study with no study product administered because it is the LTFU study for patients who received the product in another study
| Study group | Role | What they receive |
|---|---|---|
| Open Observation | All patients who previously received MB-105 on another study Receives: Biological: MB-105 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assess long term safety of MB-105 in patients who received MB-105
SAEs
Measured: 15 Years
Secondary outcomes (1)
Assess long term efficacy of MB-105 in patients who received MB-105
Time to progression/relapse in those who have not yet relapsed and overall survival
Measured: 15 Years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jan 2026
- Study start27 Feb 2026 (estimated)
- Primary completion15 Oct 2040 (estimated)
- Study completion15 Oct 2040 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Any Patient Treated With MB-105Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- March Biosciences Inc
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07340814
- Sponsor's protocol ID
- MB-105-202
- Status last verified
- Jan 2026
- First submitted
- 6 Jan 2026
- Last updated
- 14 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 14 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Long-term Follow-up Study of Patients Who Received MB-105
- ClinicalTrials.gov ID
- NCT07340814
- Acronym / sponsor ID
- MB-105-202
- Conditions
- Any Patient Treated With MB-105
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- March Biosciences IncIndustry (pharma, biotech, devices)
- Study start
- 27 Feb 2026 (estimated)
- Primary completion
- 15 Oct 2040 (estimated)
- Study completion
- 15 Oct 2040 (estimated)
- First posted
- 14 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is to fulfil the regulatory requirement for 15-year follow-up for patients treated with MB-105 in any study
Detailed description
This study is for long term follow up of efficacy and safety for any patient treated with MB-105 who has consented to joining the LTFU study. There are no exclusion criteria.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Open Observation | – | Biological: MB-105All patients who previously received MB-105 on another study |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Patients who previously received MB-105 and consent to participate
Key inclusion criteria (1 listed)
- Received MB-105 Signed informed consent Agree to transfer of samples from previous study Able to comply with study requirements
Key exclusion criteria (1 listed)
- N/A
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MB-105This is an observational study with no study product administered because it is the LTFU study for patients who received the product in another study | Biological | Open Observation |
Primary outcome
Assess long term safety of MB-105 in patients who received MB-105
Time frame: 15 Years
SAEs
1 secondary outcome
Assess long term efficacy of MB-105 in patients who received MB-105
Time frame: 15 Years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jan 2026.
- Individual participant dataSharing planned: Undecided
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Any Patient Treated With MB-105, run by March Biosciences Inc.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 14 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assess long term safety of MB-105 in patients who received MB-105 (time frame: 15 Years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jan 2026.